Siglec proteins are found on the surface of immune cells. They act like brakes, telling the immune system when to stop attacking. This helps prevent damage to the body's own tissues.
These proteins recognize specific sugar molecules on cells. When they bind, they send a signal to calm the immune response. This process is important for controlling inflammation and avoiding autoimmune reactions.
Researchers are studying how to target these Siglec pathways. By adjusting their activity, it might be possible to boost the immune system against cancer or calm it down in autoimmune diseases. This approach could lead to new treatments for a range of conditions.
The review highlights that Siglec signaling is a promising area for drug development. It could help treat infections, neurodegeneration, and inflammatory disorders. More research is needed to turn these ideas into safe and effective therapies.